ClinicalTrials.gg

Program

golidocitinib

Also written as “AZD4205”, “GW5282 combined with Golidocitinib” and “DZD9008+AZD4205”.

Its studies are mostly in Lymphoma, T-Cell, Peripheral · Carcinoma, Non-Small-Cell Lung · Lymphoma, T-Cell, led by Dizal Pharmaceuticals.

Furthest: phase 3, since Nov 14, 202510 company-led studies, 2 open or runningNext primary completion: Nov 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dizal Pharmaceuticals102 open or runningphase 3since Nov 14, 2025Jan 25, 2018Nov 30, 2027phase 3 · NCT07234162

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 25, 2018First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03450330 · 10 enrolled · Australia
  2. Oct 28, 2018Phase 1 study in Healthy VolunteersNCT03728023 · 66 enrolled · United States
  3. Sep 18, 2019Phase 2 study in RecurrenceNCT04105010 · 171 enrolled · United States, Australia, China and more
  4. Jan 3, 2020Phase 1 study in Healthy VolunteersNCT04225208 · 8 enrolled · United States
  5. Aug 2, 2022Phase 1 study in Healthy SubjectsNCT05486949 · 32 enrolled · United States
  6. Feb 7, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06295432 · 30 enrolled · China
  7. Jul 15, 20242 phase 2 studies in Lymphoma, T-Cell, PeripheralNCT06511895, NCT06511869
  8. Nov 14, 2025Phase 3 study in Lymphoma, T-Cell, PeripheralNCT07234162 · 218 planned · China, Taiwan, Thailand
  9. Mar 16, 2026Phase 2 study in Lymphoma, T-CellNCT07496229 · 220 planned · China

Ahead

  1. Nov 30, 2027Primary completion: phase 3 study in Lymphoma, T-Cell, PeripheralNCT07234162
  2. Sep 2029Primary completion: phase 2 study in Lymphoma, T-CellNCT07496229

TargetBeta

JAK1 →read by rule
“An orally available inhibitor of Janus-associated kinase 1 (JAK1), ”NCIt, by rule
“Tyrosine-protein kinase JAK1 inhibitor”ChEMBL 37, by rule

Other programs on JAK1

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
baricitinibruleEli Lillyphase 459
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
jaktinibruleSuzhou Zelgen Biopharmaceuticalsphase 331
abrocitinibrulePfizerphase 330
ivarmacitinibruleJiangsu HengRui Medicinephase 325
brepocitinibrulePfizerphase 325
delgocitinibruleLEO Pharmaphase 321
momelotinibruleGlaxoSmithKlinephase 317

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07496229Lymphoma, T-Cell · China2RecruitingSep 2029220
NCT07234162Lymphoma, T-Cell, Peripheral · China, Taiwan, Thailand3RecruitingNov 30, 2027218
NCT06511895Lymphoma, T-Cell, Peripheral · China2CompletedOct 17, 202557
NCT06511869Lymphoma, T-Cell, Peripheral · China2CompletedMar 31, 202548
NCT06295432Carcinoma, Non-Small-Cell Lung · China2CompletedJun 8, 202630
NCT05486949Healthy Subjects · United States1CompletedOct 8, 202232
NCT04225208Healthy Volunteers · United States1CompletedMar 2, 20208
NCT04105010Recurrence · United States, Australia, China and more2CompletedOct 12, 2023171
NCT03728023Healthy Volunteers · United States1CompletedAug 20, 201966
NCT03450330Carcinoma, Non-Small-Cell Lung · Australia2CompletedSep 3, 201910

How it is read

Names in the registry

  • “AZD4205”, 4 entries
  • “GW5282 combined with Golidocitinib”, 3 entries
  • “DZD9008+AZD4205”, 1 entry
  • “Golidocitinib”, 1 entry
  • “golidocitinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.